Home ›
Entities
› academia
› Sabatolimab (<scp>MBG453</scp>) model‐informed drug development for dose selection in patients with myelodysplastic syndrome/acute myeloid leukemia and solid tumors
Sabatolimab (<scp>MBG453</scp>) model‐informed drug development for dose selection in patients with myelodysplastic syndrome/acute myeloid leukemia and solid tumors
Research article (CPT Pharmacometrics & Systems Pharmacology, 2023) · cited 20× · AI/ML
Sabatolimab (MBG453) model‐informed drug development for dose selection in patients with myelodysplastic syndrome/acute myeloid leukemia and solid tumors
Summary
Sabatolimab (MBG453) model‐informed drug development for dose selection in patients with myelodysplastic syndrome/acute myeloid leukemia and solid tumors is a scholarly article[1].
Key Facts
Sabatolimab (MBG453) model‐informed drug development for dose selection in patients with myelodysplastic syndrome/acute myeloid leukemia and solid tumors's instance of is recorded as scholarly article[2].
References
Programmatic citations — every numbered marker resolves to a verifiable graph row below.
Use these citations when quoting this entity in research, articles, AI prompts, or wherever provenance matters. We aggregate Wikidata + Wikipedia + authoritative open-data sources; the stitched, scored, cross-referenced view is what 4ort.xyz contributes.
APA4ort.xyz Knowledge Graph. (2026). Sabatolimab (<scp>MBG453</scp>) model‐informed drug development for dose selection in patients with myelodysplastic syndrome/acute myeloid leukemia and solid tumors. Retrieved May 24, 2026, from https://4ort.xyz/entity/sabatolimab-scp-mbg453-scp-modelinformed-drug-development-for-dose-selection-in-patients-with-myelodysplastic-syndrome-a
MLA“Sabatolimab (<scp>MBG453</scp>) model‐informed drug development for dose selection in patients with myelodysplastic syndrome/acute myeloid leukemia and solid tumors.” 4ort.xyz Knowledge Graph, 4ort.xyz, 24 May. 2026, https://4ort.xyz/entity/sabatolimab-scp-mbg453-scp-modelinformed-drug-development-for-dose-selection-in-patients-with-myelodysplastic-syndrome-a.
BibTeX@misc{4ortxyz_sabatolimab-scp-mbg453-scp-modelinformed-drug-development-for-dose-selection-in-patients-with-myelodysplastic-syndrome-a_2026, author = {{4ort.xyz Knowledge Graph}}, title = {{Sabatolimab (<scp>MBG453</scp>) model‐informed drug development for dose selection in patients with myelodysplastic syndrome/acute myeloid leukemia and solid tumors}}, year = {2026}, url = {https://4ort.xyz/entity/sabatolimab-scp-mbg453-scp-modelinformed-drug-development-for-dose-selection-in-patients-with-myelodysplastic-syndrome-a}, note = {Accessed: 2026-05-24}}
LLM promptAccording to 4ort.xyz Knowledge Graph (aggregator of Wikidata, Wikipedia, and authoritative open-data sources): Sabatolimab (<scp>MBG453</scp>) model‐informed drug development for dose selection in patients with myelodysplastic syndrome/acute myeloid leukemia and solid tumors — https://4ort.xyz/entity/sabatolimab-scp-mbg453-scp-modelinformed-drug-development-for-dose-selection-in-patients-with-myelodysplastic-syndrome-a (retrieved 2026-05-24)
